Metrics to compare | 688759 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688759PeersSector | |
|---|---|---|---|---|
P/E Ratio | −84.0x | 10.6x | −0.5x | |
PEG Ratio | - | −0.06 | 0.00 | |
Price/Book | 8.8x | 2.4x | 2.6x | |
Price / LTM Sales | - | 5.4x | 3.2x | |
Upside (Analyst Target) | - | 33.5% | 48.1% | |
Fair Value Upside | Unlock | 22.5% | 6.6% | Unlock |
BeBetter Med Inc., a biopharmaceutical company, engages in the research and development, and sale of drugs for tumors, autoimmune diseases, and metabolic diseases. It is developing BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor; BEBT-209, a CDK4 highly selective CDK4/6 inhibitor for antitumor; BEBT-109, a pan-mutant EGFR inhibitor for antitumor; BEBT-260, a ChK1 inhibitor for antitumor; BEBT-305, a second-generation HSP90 inhibitor for autoimmune disease; BEBT-503, a pan-PPAR agonist for metabolic disease; BEBT-607, a KRAS G12C inhibitor for antitumor; BEBT-808, an oral small molecule GLP-1R full agonist for metabolic disease; BEBT-809, a GPR75 pathway inhibitor for metabolic disease; and BEBT-508, a small nucleic acid drug. The company was founded in 2012 and is based in Guangzhou, China.